- •
Cholestasis caused by drugs is an important liver disease in patients with a biochemical cholestatic pattern and normal hepatobiliary imaging.
- •
Cholestatic drug-induced liver injury (DILI) is more common than hepatocellular DILI among the elderly.
- •
Most cases of cholestatic DILI are mild but in rare cases, ductopenia and cholestatic cirrhosis can develop.
- •
Approximately 10% of patients with cholestatic jaundice caused by drugs develop liver failure.
Drug-Induced Cholestasis
Section snippets
Key points
Approach to the patient with suspected drug-induced cholestatic liver injury
The clinical presentation of cholestatic liver disease is variable. Asymptomatic increase in liver enzymes can be observed, particularly increased ALP, but jaundice with or without pruritus is a common presentation. Some patients present with fever and abdominal pain that can simulate gallstone disease. Because some patients can have stones in the gallbladder, this can lead to unnecessary cholecystectomies. Unfortunately, there is no marker of hepatotoxicity that is completely reliable and
Incidence of cholestatic liver injury caused by drugs
Limited data exist on the incidence of DILI with cholestatic reactions included in the general population. A landmark population-based study on the incidence of DILI in society was undertaken in France in a defined population and revealed an incidence of 13.9 cases per 100,000 per year.14 Thirty-three percent of cases had a cholestatic or mixed pattern.14 In the largest series, cholestatic pattern was present in 20% to 40%, mixed pattern in 12% to 20% and hepatocellular pattern in 48% to 58% (
Chemical Properties of Drugs
For most drugs, little is known about the risk of DILI for the individual patient. The chemical properties of some drugs have indicated that some have hepatotoxic potential. Temafloxacin and trovafloxacin have a unique difluorinated side chain that does not occur in other quinolones. This makes these drugs extra lipophilic and they are associated with cholestatic liver disease.15 Drugs given orally in a daily dose of more than 50 mg are much more likely to lead to DILI than those with a lower
Vanishing bile duct syndrome
Chronic intrahepatic cholestatic patterns are rarely associated with DILI. The liver histology can mimic that of primary biliary cirrhosis with granulomatous duct injury.31 Vanishing bile duct syndrome is a rare syndrome and has been considered to occur in only 0.5% of cases of small duct biliary disease.32 In a minority of patients, progressive ductopenia occurs, which can lead to near complete absence of ducts with variable amount of inflammation.33 This is diagnosed mainly in patients with
The pathology of drug-induced cholestasis
For almost 2 centuries, pathologists have recognized morphologic changes in the liver in jaundiced patients,46, 47 although the molecular basis for cholestasis has only been revealed in the last 2 to 3 decades.48 There is a long tradition in pathology to use the term cholestasis in pathology reports on liver tissue. This morphologic cholestasis refers to the deposition of bile in hepatocytes and/or the biliary passages of the liver tissue, which can be detected under the microscope.49 The
The pathophysiology of drug-induced cholestasis
Hepatic detoxification of xenobiotics involves either phase I reactions followed by phase II reactions or phase I alone or rarely only phase II.55 Phase II reactions result in anionic conjugates with sulfate, glucuronate, or glutathione. These drug metabolites are transported across hepatocyte membranes by transporters (uptake or efflux transporters) on the apical or the canalicular membranes.56 This hepatic drug transport has been shown to be involved in the pathophysiology of cholestatic
Most important drugs leading to cholestatic liver injury
The list of drugs associated with cholestatic injury is long. A comprehensive list of drugs reported to have induced hepatotoxicity has been published.67 This article focuses on the most common types of drugs and new observations in this context.
The prognosis of patients with cholestasis caused by drugs
Drug-induced jaundice has been associated with a poor prognosis4 and a severe drug reaction on the liver was found by Hy Zimmerman to lead to at least 10% mortality.4 This has been named Hy’s law and was later validated in a large series of patients with DILI; the mortality/liver transplantation rate was 9% to 12%.5, 20, 68 Originally, this association was believed to be true only for hepatocellular jaundice, and the prognosis of those with cholestatic injury was mainly related to comorbidities
References (119)
- et al.
Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge
J Clin Epidemiol
(1993) - et al.
Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries
J Clin Epidemiol
(1993) - et al.
Incidence of drug-induced hepatic injuries: a French population-based study
Hepatology
(2002) - et al.
Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis
J Hepatol
(2011) - et al.
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period
Gastroenterology
(2005) - et al.
Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease
Gastroenterology
(1997) - et al.
Effects of long-term rifampicin administration in primary biliary cirrhosis
Gastroenterology
(1992) - et al.
HLA association of amoxicillin-clavulanate–induced hepatitis
Gastroenterology
(1999) - et al.
Liver damage from flucloxacillin, cloxacillin and dicloxacillin
J Hepatol
(1992) Vanishing bile duct syndrome in drug-induced liver disease
J Hepatol
(1997)
Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis
J Hepatol
Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome
Gastroenterology
Enterohepatic transport of bile salts and genetics of cholestasis
J Hepatol
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
Hepatology
Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats
Gastroenterology
Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs
Gastroenterol Clin Biol
Hepatotoxicity due to antibiotics
Clin Liver Dis
Terbinafine hepatotoxicity. A case report and review of literature
Ann Hepatol
Cholestatic hepatitis related to quinolones: a report of two cases
J Hepatol
Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease
J Hepatol
Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis
Dig Liver Dis
The pathology of drug-induced liver injury
Semin Liver Dis
Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver
Outcome and prognostic markers in severe drug-induced liver disease
Hepatology
Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis
Hepatology
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury
Hepatology
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method
Hepatology
Causality assessment in drug-induced liver injury
Semin Liver Dis
Stevens-Johnson syndrome and cholestatic hepatitis induced by acute Epstein-Barr virus infection
Eur J Gastroenterol Hepatol
Cholestatic hepatitis in a patient with typhoid fever - a case report
Ann Clin Microbiol Antimicrob
A case of acute q Fever with severe acute cholestatic hepatitis
Gut Liver
Weight loss and severe jaundice in a patient with hyperthyroidism
Z Gastroenterol
Trovafloxacin-induced acute hepatitis
Clin Infect Dis
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury (DILI). Search for signals
Hepatology
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender
Hepatology
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
Hepatology
Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver
Hepatology
Hepatobiliary complications of oral contraceptives
J Gen Intern Med
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Gut
Co-amoxiclav jaundice: clinical and histological features and HLA class II association
Gut
HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease
Hepatology
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Nat Genet
Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump
World J Gastroenterol
Primary biliary cirrhosis after long-term practolol administration
Br Med J
Idiopathic adulthood ductopenia: an update
Mayo Clin Proc
Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia
Hepatology
Reversible vanishing bile duct syndrome induced by carbamazepine
Eur J Gastroenterol Hepatol
Drug-induced cholestasis
Hepatology
Chronic cholestasis following prolonged tolbutamide administration
Arch Pathol
Biliary cirrhosis following administration of methyltestosterone
JAMA
Cited by (49)
Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins
2023, MacSween's Pathology of the Liver, Eighth EditionDrug-Induced Liver Injury
2022, Comprehensive PharmacologyBile canaliculi contract autonomously by releasing calcium into hepatocytes via mechanosensitive calcium channel
2020, BiomaterialsCitation Excerpt :In summary, hyperactivation of Piezo-1 can rescue BC contractility and prevent the stasis of bile. Hepatocellular cholestasis is severely implicated in drug-induced liver injury and is one of the major reasons for drug withdrawal [37,38]. Hepatocellular cholestasis inducing drugs have been found to disrupt the activity of the transporters on the BC membrane, which cause BA build-up in the hepatocytes and reduced bile flow [5].
Cholestatic liver injury induced by food additives, dietary supplements and parenteral nutrition
2020, Environment InternationalCitation Excerpt :Cholestasis describes any situation of impaired bile flow within the liver as such (intrahepatic cholestasis) or in the biliary tree (extrahepatic cholestasis) leading to the accumulation of toxic levels of bile acids (BAs) (Tanaka et al., 2017). In adult patients it is usually depicted as an increase in serum levels of alkaline phosphatase (ALP) to more than twice the upper limit of normal and an alanine aminotransferase (ALT) to ALP ratio (ALT/ALP) below 2 (Bjornsson and Jonasson, 2013). Additionally, although hyperbilirubinemia is not a synonym of cholestasis, cholestatic injury usually leads to impaired conjugated bilirubin excretion.
Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems
2018, Food and Chemical Toxicology